United StatesBreaking News

WisdomTree (NYSE:WT) announced that its firm-wide assets under management reached an all-time high in May 2026, fueled by record asset volumes across its U.S., European, and Digital Asset segments, alongside the formal closing of a key international acquisition.

Hooker Furnishings (NASDAQ:HOFT) reported a return to profitability for its fiscal 2027 first quarter, driven by sharp gross margin expansion and resilient performance across its core segments, even as soft consumer demand continues to drag on top-line retail furniture sales.

Oracle shares declined in premarket trading after the company reported quarterly capital expenses that were higher than estimates. The company expects to spend about $70 billion on net capital expenditures in the current fiscal year, which ends in May 2027. Bloomberg Intelligence's Matthew Bloxham has more.

Recursive Co-Founder Tim Rocktäschel speaks with Bloomberg's Tom Mackenzie from the Founders Forum in Oxfordshire, UK.

The week SpaceX launches its highly-anticipated initial public offering. Chairman and CEO of Voyager Technologies Dylan Taylor says ultimately more attention on the space sector will be good for the industry as a whole. Taylor spoke to Bloomberg TV's Francine Lacqua on Wednesday June 10.

On Friday, SpaceX launches its highly-anticipated initial public offering in what is set to be the largest listing in history. Dylan Taylor, Chairman and CEO of aerospace and defense company Voyager Technologies says he's "bullish and optimistic" about the impact it will have on the industry, saying he believes there will be a lot of capital that "flows back into other space names as well" . In an interview with Francine Lacqua on Bloomberg TV on Wednesday June 10, Taylor also discussed plans for habitation on the moon, the importance of the Artemis mission as well as the space race.

Cellectis (NASDAQ:CLLS) reported highly encouraging clinical updates for its off-the-shelf, gene-edited cancer therapies, highlighting a perfect overall response rate in a target group of leukemia patients.

Vertex Pharmaceuticals (NASDAQ:VRTX) announced highly anticipated clinical data demonstrating that its CRISPR-based gene-editing therapy, CASGEVY, matches its highly successful adult profile when used in younger children.

Johnson & Johnson (NYSE:JNJ) reported positive data from a late-stage clinical trial for its drug Imaavy, strengthening its bid to secure the first regulatory approval for a rare, life-threatening autoimmune blood disorder.

Anna Edwards, Guy Johnson and Mark Cudmore break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade."

The effective closure of the Strait of Hormuz and previous Red Sea disruptions will continue to impact freight capacity and rates for longer, even as global customer demand for both sea and air services is holding up, according to DHL Group's's CEO for Global Forwarding Oscar de Bok. De Bok discussed these and some of the other effects of the ongoing Iran war with BTV's Oliver Crook during Bloomberg Daybreak Europe.

Robeco's Thu Ha Chow sees Indonesia's out-of-cycle interest rate hike this week as reflecting policymakers' willingness to address investor concerns. Speaking on The China Show, Chow added that while Indonesia is at the beginning of a turnaround story, it's not quite there yet.